510(k) device
Icare HOME Tonometer
Icare Finland OY · Tonometer, Manual (HKY, Class II) · First FDA decision Mar 21, 2017, newest May 7, 2020Glaucoma
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
6
Naming "Icare HOME"
MAUDE reports
0
Brand "Icare HOME", since 2015
PubMed studies
53
Mentioning "Icare HOME"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Icare HOME Tonometer510(k)
K200966 · Decided May 7, 2020 · 27 days after receipt
Device type: Tonometer, Manual (HKY) · Ophthalmology
- Icare HOME tonometer510(k)
K163343 · Decided Mar 21, 2017 · 112 days after receipt
Device type: Tonometer, Manual (HKY) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Home Health Plans of Care: Monitoring Glucose Control in the Medicare Home Health Population with Type II Diabetes MellitusLocal determinationIn effectL35132Palmetto GBAUpdated Apr 9, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Icare HOME", any status and sponsor, newest update first.
- Impact of Home Intraocular Pressure Telemonitoring on Intraocular Pressure Control and Glaucoma ProgressionPivotal-lookingRecruiting
The University of Hong KongAcademic, hospital or other
NCT05940623 · 142 participants (planned) · Start Sep 18, 2025 · Primary completion Jun 30, 2028
Device: Home IOP telemonitoring with smart phone-based intervention · For: Glaucoma; Intraocular Pressure; Primary Open Angle Glaucoma
Sites: Wong Chuk Hang, Hong Kong
Barron Associates, Inc.Not on our public-company list
NCT03066063 · 92 participants · Start May 7, 2019 · Primary completion Feb 28, 2022
Device: iCare · For: Amblyopia; Ocular Motility Disorders
Sites: Memphis, Tennessee
NHS LothianGovernment (non-federal)
NCT03057301 · 100 participants (planned) · Start Apr 1, 2016 · Primary completion May 17, 2017
Device: iCare home tonometer · For: Glaucoma; Intraocular Pressure
Sites: Edinburgh, United Kingdom
Luzerner KantonsspitalAcademic, hospital or other
NCT04485897 · 25 participants (planned) · Start Nov 26, 2020 · Primary completion Aug 1, 2024
Device: icare HOME device (Icare Oy, Vanda, Finland) · For: Intraocular Pressure
Sites: Lucerne, Switzerland
St. Erik Eye HospitalAcademic, hospital or other
NCT04911387 · 61 participants · Start Apr 1, 2020 · Primary completion Oct 31, 2020
Device: Intraocular pressure measurments · For: Glaucoma; Open Angle Glaucoma; Ocular Hypertension and 1 more
Sites: Stockholm, Sweden
- ICare Self-tonometry - A Head-to-head Comparison to the Gold Standard Goldmann TonometerStatus unknown
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT01733550 · 30 participants (planned) · Start Nov 2012 · Primary completion Apr 2013
Device: Home iCare (study nurse); goldmann applanation tonometry and 1 more · For: Glaucoma
Sites: Leuven, Belgium
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Icare HOME", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code HKY
4 reports: 0 malfunction, 3 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Icare HOME"[tiab]. The summary above synthesizes these.
- Home iCare - What we already know.
Lauwers M, Vandewalle E, Lemmens S · Saudi J Ophthalmol · 2024
- Impact of self-tonometry on glaucoma treatment decision.
Quérat L, Chen E · Acta Ophthalmol · 2023
- Icare Home Tonometer: A Review of Characteristics and Clinical Utility.
Liu J, De Francesco T, Schlenker M, et al. · Clin Ophthalmol · 2020Review
- Performance of home-based self-tonometry (iCare HOME (TA022)) for measuring intraocular pressure among healthy and glaucoma patients.
Nayak A, Ramesh SV, Kuzhuppilly NIR, et al. · F1000Res · 2023
- Home monitoring devices for glaucoma.
Mansoori T, Chaturvedi AK, Kong GY, et al. · Indian J Ophthalmol · 2026Review
- Clinical utility, feasibility of home tonometry using iCare HOME by glaucoma patients.
Kadambi SV, Aishwarya M, Leelavathy C, et al. · Indian J Ophthalmol · 2023
- iCare® Home vs Goldmann applanation tonometry: Agreement of methods and comparison of inter-observer variation at a tertiary eye centre.
Quérat L, Chen E · Eur J Ophthalmol · 2023
- Teaching home tonometry using a remote video link.
Barbour-Hastie CC, Tatham AJ · Eye (Lond) · 2023
- Self-measurement with Icare HOME tonometer, patients' feasibility and acceptability.
Cvenkel B, Velkovska MA, Jordanova VD · Eur J Ophthalmol · 2020Comparative Study
- Icare® rebound tonometers: review of their characteristics and ease of use.
Nakakura S · Clin Ophthalmol · 2018Review
- Clinical Use of iCare Home® tonometer.
Quérat L, Chen E · Acta Ophthalmol · 2020Letter
- Comparison of Icare HOME and non-contact tonometer in intraocular pressure measurement in the early stage after ICL V4c implantation.
Ye Y, Yang F, Ding L, et al. · Eur J Ophthalmol · 2022
Other devices of this type
Also filed under product code HKY.
- iCare IC200Icare Finland OY · 510(k) 2022
- Applanation tonometer AT-2Takagi Seiko Co., Ltd. · 510(k) 2018
- iCare ST500 (TA04)Icare Finland OY · 510(k) 2024
- Tono-Vera® Tonometer and Ocu-Dot® Tonometer Probes (16305, 16306, 16318)Reichert, Inc. · 510(k) 2024
- CATS-L Tonometer PrismCats Tonometer, LLC · 510(k) 2024
- Applanation Tonometer HT-5000Huvitz Co., Ltd. · 510(k) 2023
- iCare HOME2Icare Finland OY · 510(k) 2022
- CATS®-D Tonometer PrismCats Tonometer, LLC · 510(k) 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.